Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nuvation Bio (NUVB) Cash & Equivalents (2023 - 2025)

Nuvation Bio (NUVB) has disclosed Cash & Equivalents for 3 consecutive years, with $164.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Equivalents rose 359.33% to $164.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $164.1 million, a 359.33% increase, with the full-year FY2025 number at $164.1 million, up 359.33% from a year prior.
  • Cash & Equivalents was $164.1 million for Q4 2025 at Nuvation Bio, up from $98.9 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $248.0 million in Q2 2025 to a low of $24.4 million in Q3 2023.
  • A 3-year average of $70.1 million and a median of $39.2 million in 2023 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: tumbled 31.52% in 2024, then skyrocketed 623.26% in 2025.
  • Nuvation Bio's Cash & Equivalents stood at $42.6 million in 2023, then decreased by 16.24% to $35.7 million in 2024, then soared by 359.33% to $164.1 million in 2025.
  • Per Business Quant, the three most recent readings for NUVB's Cash & Equivalents are $164.1 million (Q4 2025), $98.9 million (Q3 2025), and $248.0 million (Q2 2025).